Novavax’s COVID-19 vaccine enters Phase 1 trials – is Moderna in trouble?

A vaccine is an unlikely solution. However, biotechs often tirelessly work on vaccines even after the expiration date of a virus. For example, vaccines for ebola, Zika, and Sars2 are still in development. Thus if a vaccine is unattainable before COVID-19 fizzles out, biotechs will continue to create a vaccine. Because we do not want […]

Novavax look to be the COVID-19 vaccine winner after surging 120%.

Novavax (NASDAQ:NVAX) is set to surge come market open with pre-market up 13% (at the time of writing). Novavax captured the wallets of investors last week when they received $384 million in vaccine funding from CEPI. This week NVAX is expected to captivate investors with a new all time-high. Which seems achievable especially if last […]